

## Agilus Diagnostics installs Illumina NovaSeq X to revolutionise genomic testing in India

28 January 2026 | News

### NovaSeq X strengthens Agilus Diagnostics' molecular testing capabilities



Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory—strengthening India’s capacity for next-generation sequencing at scale.

The launch was attended by Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare; Dr Anand K., Managing Director & CEO, Agilus Diagnostics, and Deepak Narang, Chief Operating Officer, Agilus Diagnostics.

The NovaSeq X strengthens Agilus Diagnostics’ molecular testing capabilities through high-throughput sequencing and scalable analytics. Its multi-omic capacity delivers rapid, high-resolution results across diverse clinical needs. Through Agilus’ nationwide network, these advanced capabilities become accessible to clinicians and patients in both metro and emerging markets.

Powered by high-density flow cells and automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multi-omic analysis with exceptional speed and accuracy. Deployed for high-fidelity clinical decision-making—not just research—it provides physicians with actionable molecular insights and faster turnaround times.

Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High-quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalized and preventive care.

Agilus' investment brings cutting-edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions."

For clinicians and researchers, the enhanced capacity translates into:

- Whole exome and whole genome testing for comprehensive variant detection
- Genetic evaluation of inherited and rare disorders
- Reproductive and maternal health applications, including carrier screening and prenatal testing
- Pharmacogenomic assessments to inform drug response and dosing
- Infectious disease sequencing for pathogen tracking and antimicrobial resistance insights
- Liquid biopsy (ctDNA) analysis and multi-omic studies for longitudinal disease monitoring and deeper biological understanding